• Takeda, Sosei form gastrointestinal disease R&D pact fiercepharma
    August 13, 2019
    Takeda and Sosei Heptares have entered into a multitarget R&D agreement. Sosei is set to receive $26 million (€23 million) in upfront and near-term payments, plus up to $1.2 billion in milestones, to apply its GPCR expertise to targets of interest to Take
PharmaSources Customer Service